search
Back to results

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer (EMBER)

Primary Purpose

Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer

Status
Active
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
LY3484356
Abemaciclib
Everolimus
Alpelisib
Trastuzumab
Aromatase Inhibitor (AI)
Pertuzumab
Sponsored by
Eli Lilly and Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

All study parts:

  • Participants must be willing to provide adequate archival tissue sample
  • Participants must be willing to use highly effective birth control
  • Participants must have adequate organ function
  • Participants must be able to swallow capsules

Dose escalation- Participants must have one of the following:

  • Parts A and B: ER+ HER2- breast cancer with evidence of locally advanced unresectable or metastatic disease who have had the following:
  • Part A: may have had up to 1 prior regimen of any kind for in the advanced/metastatic setting and no prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy.
  • Part B: may have had up to 2 prior regimens, no more than 1 of which may be endocrine therapy in the advanced/metastatic setting, and must have received a prior CDK4/6 inhibitor
  • Cohort E4: No prior everolimus.
  • Cohort E5: No prior alpelisib and must have a phosphatidylinositol 3-kinase catalytic α (PIK3Cα) mutation as determined by local testing.
  • Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer with evidence of locally advanced unresectable or metastatic disease who have had at least 2 HER2-directed therapies in any setting.
  • Part D: ER+, EEC that has progressed after platinum containing chemotherapy and no prior fulvestrant or aromatase inhibitor therapy.
  • Part E: ER+ and HER2+ breast cancer with evidence of locally advanced, unresectable, or metastatic disease.
  • Part E: Participants must have received induction taxane chemotherapy combined with trastuzumab + pertuzumab as first-line treatment for advanced/metastatic disease and must not have progressed on this regimen.
  • Part E: Participants must not have received more than 1 HER2-directed regimen or any endocrine therapy for advanced disease or any prior CDK4/6 inhibitor therapy.

Participants with ER+/HER2- breast cancer enrolled in this study must have had evidence of clinical benefit while on endocrine therapy for at least 24 months in the adjuvant setting or at least 6 months in the advanced/metastatic setting or have untreated de novo metastatic breast cancer

Exclusion Criteria:

  • Participants must not have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
  • Participants must not have another serious medical condition
  • Participants must not have cancer of the central nervous system that is unstable
  • Participants must not be pregnant or breastfeeding

Sites / Locations

  • Banner MD Anderson Cancer Center
  • Mayo Clinic Hospital
  • Highlands Oncology Group
  • Beverly Hills Cancer Center
  • Univ of California Irvine College of Medicine
  • Univ of California San Francisco
  • Rocky Mountain Cancer Center
  • Mayo Clinic in Florida
  • Lake Nona DDU
  • Winship Cancer Center Emory University
  • Northwestern University
  • Community Health Network
  • Johns Hopkins University
  • Massachusetts General Hospital
  • Dana-Farber Cancer Institute
  • Minnesota Oncology/Hematology PA
  • Mayo Clinic
  • Washington University Medical School
  • Memorial Sloan Kettering Cancer Center
  • Memorial Sloan Kettering Cancer Center
  • University of Rochester School of Medicine
  • University of North Carolina
  • Duke University Medical Center
  • Ohio State University Medical Center
  • Peggy and Charles Stephenson Oklahoma Cancer Center
  • Asante Rogue Regional Medical Center
  • University of Pittsburgh Medical Center
  • Rhode Island Hospital
  • Sarah Cannon Research Institute SCRI
  • Tennessee Oncology PLLC
  • Henry-Joyce Cancer Clinic
  • Texas Oncology-Baylor Charles A. Sammons Cancer Center
  • UT Southwestern Med Center
  • University of Texas MD Anderson Cancer Center
  • South Texas Accelerated Research Therapeutics (START)
  • Texas Oncology - San Antonio Medical Center
  • US Oncology
  • Texas Oncology - Tyler
  • University of Vermont Medical Center
  • Inova Schar Cancer Institute
  • Oncology and Hematology Associates of Southwest Virginia Inc
  • Seattle Cancer Care Alliance
  • St Vincent's Hospital Sydney
  • Calvary Mater Newcastle
  • Ashford Cancer Centre Research
  • Breast Cancer Research Centre-WA
  • Linear Clinical Research
  • Institut Jules Bordet
  • Universitair Ziekenhuis Antwerpen
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
  • Institut Curie
  • Institut de Cancérologie de l'Ouest Centre René Gauducheau
  • ICANS_Institut de Cancerologie Strasbourg Europe
  • Gustave Roussy
  • Hyogo Cancer Center
  • National Cancer Center Hospital
  • Severance Hospital, Yonsei University Health System
  • Seoul National University Hospital
  • Asan Medical Center
  • Samsung Medical Center
  • Hospital Universitari Vall d'Hebron
  • Hospital Clinic I Provincial
  • Hospital General Universitario Gregorio Marañon
  • Hospital Universitario Ramón y Cajal
  • Hospital Clinico San Carlos
  • Hospital Universitario 12 de Octubre
  • Fundación Jiménez Díaz-Oncology
  • Hospital Madrid Norte Sanchinarro
  • Fundación Instituto Valenciano de Oncología
  • Hospital Clínico Universitario de Valencia
  • Kaohsiung Medical University Chung-Ho Memorial Hospital
  • China Medical University Hospital
  • National Cheng-Kung Uni. Hosp.
  • National Taiwan University Hospital
  • Mackay Memorial Hospital
  • Taipei Veterans General Hospital

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm 6

Arm 7

Arm 8

Arm Type

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Experimental

Arm Label

Dose Escalation LY3484356

Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI

Part B: Dose Expansion: Cohort E3: LY3484356

Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus

Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib

Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib

Part D: Dose Expansion: LY3484356 +/- Abemaciclib

Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab

Arm Description

LY3484356 given orally.

LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.

LY3484356 given orally.

LY3484356 and everolimus given orally.

LY3484356 and alpelisib given orally.

LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.

LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.

LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.

Outcomes

Primary Outcome Measures

Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
Number of Participants with DLTs and DLT-Equivalent Toxicities

Secondary Outcome Measures

Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3484356
PK: AUC of LY3484356
PK: Maximum Concentration (Cmax) of LY3484356
PK: Cmax of LY3484356
PK: AUC of LY3484356 in Combination with Other Anticancer Therapies
PK: AUC of LY3484356 in Combination with Other Anticancer Therapies
PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies
PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies
Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
ORR: Percentage of Participants with Confirmed CR or PR as per RECIST v1.1
Duration of Response (DoR): Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
DoR: Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response (BOR) of CR, PR, and Stable Disease (SD) as per RECIST v1.1
DCR: Percentage of Participants with a BOR of CR, PR, and SD as per RECIST v1.1
Clinical Benefit Rate (CBR): Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1
CBR: Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1
Progression Free Survival (PFS): Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
PFS: Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier

Full Information

First Posted
November 18, 2019
Last Updated
April 12, 2023
Sponsor
Eli Lilly and Company
search

1. Study Identification

Unique Protocol Identification Number
NCT04188548
Brief Title
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
Acronym
EMBER
Official Title
EMBER: A Phase 1a/1b Study of LY3484356 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With ER+ Locally Advanced or Metastatic Breast Cancer and Other Select Non-Breast Cancers
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
December 10, 2019 (Actual)
Primary Completion Date
June 29, 2020 (Actual)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eli Lilly and Company

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The reason for this study is to see if the study drug LY3484356 alone or in combination with other anticancer therapies is safe and effective in participants with advanced or metastatic breast cancer or endometrial cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
500 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Dose Escalation LY3484356
Arm Type
Experimental
Arm Description
LY3484356 given orally.
Arm Title
Part A: Dose Expansion: LY3484356 + Abemaciclib +/- AI
Arm Type
Experimental
Arm Description
LY3484356 and abemaciclib given orally in combination with or without Aromatase Inhibitor (AI) of physician's choice (Anastrozole, Exemestane, or Letrozole) administered orally.
Arm Title
Part B: Dose Expansion: Cohort E3: LY3484356
Arm Type
Experimental
Arm Description
LY3484356 given orally.
Arm Title
Part B: Dose Expansion: Cohort E4: LY3484356 + Everolimus
Arm Type
Experimental
Arm Description
LY3484356 and everolimus given orally.
Arm Title
Part B: Dose Expansion: Cohort E5: LY3484356 + Alpelisib
Arm Type
Experimental
Arm Description
LY3484356 and alpelisib given orally.
Arm Title
Part C:Dose Expansion: LY3484356 + Trastuzumab +/- Abemaciclib
Arm Type
Experimental
Arm Description
LY3484356 administered orally in combination with trastuzumab intravenously with or without Abemaciclib.
Arm Title
Part D: Dose Expansion: LY3484356 +/- Abemaciclib
Arm Type
Experimental
Arm Description
LY3484356 and Abemaciclib given orally with trastuzumab administered intravenously.
Arm Title
Part E: Dose Expansion: LY3484356 + Trastuzumab + Pertuzumab
Arm Type
Experimental
Arm Description
LY3484356 administered orally in combination with trastuzumab and pertuzumab administered intravenously.
Intervention Type
Drug
Intervention Name(s)
LY3484356
Other Intervention Name(s)
Imlunestrant
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Abemaciclib
Other Intervention Name(s)
LY2835219
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Everolimus
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Alpelisib
Intervention Description
Administered orally
Intervention Type
Drug
Intervention Name(s)
Trastuzumab
Intervention Description
Administered intravenously
Intervention Type
Drug
Intervention Name(s)
Aromatase Inhibitor (AI)
Intervention Description
Anastrozole or Exemestane or Letrozole administered orally (physician choice)
Intervention Type
Drug
Intervention Name(s)
Pertuzumab
Intervention Description
Administered intravenously
Primary Outcome Measure Information:
Title
Number of Participants with Dose Limiting Toxicities (DLTs) and DLT-Equivalent Toxicities
Description
Number of Participants with DLTs and DLT-Equivalent Toxicities
Time Frame
Baseline through Cycle 1 (21/28 Day Cycle)
Secondary Outcome Measure Information:
Title
Pharmacokinetics (PK): Area Under the Concentration Time Curve (AUC) of LY3484356
Description
PK: AUC of LY3484356
Time Frame
Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)
Title
PK: Maximum Concentration (Cmax) of LY3484356
Description
PK: Cmax of LY3484356
Time Frame
Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)
Title
PK: AUC of LY3484356 in Combination with Other Anticancer Therapies
Description
PK: AUC of LY3484356 in Combination with Other Anticancer Therapies
Time Frame
Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)
Title
PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies
Description
PK: Cmax of LY3484356 in Combination with Other Anticancer Therapies
Time Frame
Predose Cycle 1 Day 1 through Predose Cycle 2 Day 1 (21/28 Day Cycles)
Title
Overall Response Rate (ORR): Percentage of Participants with Confirmed Complete Response (CR) or Partial Response (PR) as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Description
ORR: Percentage of Participants with Confirmed CR or PR as per RECIST v1.1
Time Frame
Baseline through Disease Progression or Death (Estimated up to 28 Months)
Title
Duration of Response (DoR): Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
Description
DoR: Time From the Date of First Evidence of CR, PR (per RESIST v1.1) to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
Time Frame
Date of CR or PR to Date of Objective Disease Progression or Death Due to Any Cause (Estimated up to 28 Months)
Title
Disease Control Rate (DCR): Percentage of Participants with a Best Overall Response (BOR) of CR, PR, and Stable Disease (SD) as per RECIST v1.1
Description
DCR: Percentage of Participants with a BOR of CR, PR, and SD as per RECIST v1.1
Time Frame
Baseline through Measured Progressive Disease (Estimated up to 28 Months)
Title
Clinical Benefit Rate (CBR): Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1
Description
CBR: Percentage of Participants with a BOR of CR or PR, or SD lasting ≥24 weeks as per RECIST v1.1
Time Frame
Baseline through Measured Progressive Disease (Estimated up to 28 Months)
Title
Progression Free Survival (PFS): Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
Description
PFS: Time From Baseline to the Date of Objective Progression or Death Due to Any Cause, Whichever is Earlier
Time Frame
Baseline to Objective Progression or Death Due to Any Cause (Estimated up to 28 Months)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All study parts: Participants must be willing to provide adequate archival tissue sample Participants must be willing to use highly effective birth control Participants must have adequate organ function Participants must be able to swallow capsules Dose escalation- Participants must have one of the following: Parts A and B: ER+ HER2- breast cancer with evidence of locally advanced unresectable or metastatic disease who have had the following: Part A: may have had up to 1 prior regimen of any kind for in the advanced/metastatic setting and no prior cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy. Part B: may have had up to 2 prior regimens, no more than 1 of which may be endocrine therapy in the advanced/metastatic setting, and must have received a prior CDK4/6 inhibitor Cohort E4: No prior everolimus. Cohort E5: No prior alpelisib and must have a phosphatidylinositol 3-kinase catalytic α (PIK3Cα) mutation as determined by local testing. Part C: ER+, human epidermal growth factor receptor 2 positive (HER2+) breast cancer with evidence of locally advanced unresectable or metastatic disease who have had at least 2 HER2-directed therapies in any setting. Part D: ER+, EEC that has progressed after platinum containing chemotherapy and no prior fulvestrant or aromatase inhibitor therapy. Part E: ER+ and HER2+ breast cancer with evidence of locally advanced, unresectable, or metastatic disease. Part E: Participants must have received induction taxane chemotherapy combined with trastuzumab + pertuzumab as first-line treatment for advanced/metastatic disease and must not have progressed on this regimen. Part E: Participants must not have received more than 1 HER2-directed regimen or any endocrine therapy for advanced disease or any prior CDK4/6 inhibitor therapy. Participants with ER+/HER2- breast cancer enrolled in this study must have had evidence of clinical benefit while on endocrine therapy for at least 24 months in the adjuvant setting or at least 6 months in the advanced/metastatic setting or have untreated de novo metastatic breast cancer Exclusion Criteria: Participants must not have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled Participants must not have another serious medical condition Participants must not have cancer of the central nervous system that is unstable Participants must not be pregnant or breastfeeding
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Organizational Affiliation
Eli Lilly and Company
Official's Role
Study Director
Facility Information:
Facility Name
Banner MD Anderson Cancer Center
City
Gilbert
State/Province
Arizona
ZIP/Postal Code
85234
Country
United States
Facility Name
Mayo Clinic Hospital
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85054
Country
United States
Facility Name
Highlands Oncology Group
City
Fayetteville
State/Province
Arkansas
ZIP/Postal Code
72703
Country
United States
Facility Name
Beverly Hills Cancer Center
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Univ of California Irvine College of Medicine
City
Orange
State/Province
California
ZIP/Postal Code
92868
Country
United States
Facility Name
Univ of California San Francisco
City
San Francisco
State/Province
California
ZIP/Postal Code
94158
Country
United States
Facility Name
Rocky Mountain Cancer Center
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80012
Country
United States
Facility Name
Mayo Clinic in Florida
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Lake Nona DDU
City
Orlando
State/Province
Florida
ZIP/Postal Code
32827
Country
United States
Facility Name
Winship Cancer Center Emory University
City
Atlanta
State/Province
Georgia
ZIP/Postal Code
30322
Country
United States
Facility Name
Northwestern University
City
Chicago
State/Province
Illinois
ZIP/Postal Code
60611
Country
United States
Facility Name
Community Health Network
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46250
Country
United States
Facility Name
Johns Hopkins University
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21287
Country
United States
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
Facility Name
Dana-Farber Cancer Institute
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02215
Country
United States
Facility Name
Minnesota Oncology/Hematology PA
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55404
Country
United States
Facility Name
Mayo Clinic
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
Washington University Medical School
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
Commack
State/Province
New York
ZIP/Postal Code
11725
Country
United States
Facility Name
Memorial Sloan Kettering Cancer Center
City
New York
State/Province
New York
ZIP/Postal Code
10065
Country
United States
Facility Name
University of Rochester School of Medicine
City
Rochester
State/Province
New York
ZIP/Postal Code
14642
Country
United States
Facility Name
University of North Carolina
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27599
Country
United States
Facility Name
Duke University Medical Center
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27710
Country
United States
Facility Name
Ohio State University Medical Center
City
Columbus
State/Province
Ohio
ZIP/Postal Code
43210
Country
United States
Facility Name
Peggy and Charles Stephenson Oklahoma Cancer Center
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Asante Rogue Regional Medical Center
City
Medford
State/Province
Oregon
ZIP/Postal Code
97504
Country
United States
Facility Name
University of Pittsburgh Medical Center
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Rhode Island Hospital
City
Providence
State/Province
Rhode Island
ZIP/Postal Code
02903
Country
United States
Facility Name
Sarah Cannon Research Institute SCRI
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Tennessee Oncology PLLC
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37203
Country
United States
Facility Name
Henry-Joyce Cancer Clinic
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States
Facility Name
Texas Oncology-Baylor Charles A. Sammons Cancer Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75246
Country
United States
Facility Name
UT Southwestern Med Center
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
University of Texas MD Anderson Cancer Center
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-4009
Country
United States
Facility Name
South Texas Accelerated Research Therapeutics (START)
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78229-3307
Country
United States
Facility Name
Texas Oncology - San Antonio Medical Center
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Facility Name
US Oncology
City
The Woodlands
State/Province
Texas
ZIP/Postal Code
77380
Country
United States
Facility Name
Texas Oncology - Tyler
City
Tyler
State/Province
Texas
ZIP/Postal Code
75702
Country
United States
Facility Name
University of Vermont Medical Center
City
Burlington
State/Province
Vermont
ZIP/Postal Code
05401
Country
United States
Facility Name
Inova Schar Cancer Institute
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Oncology and Hematology Associates of Southwest Virginia Inc
City
Roanoke
State/Province
Virginia
ZIP/Postal Code
24014
Country
United States
Facility Name
Seattle Cancer Care Alliance
City
Seattle
State/Province
Washington
ZIP/Postal Code
98109
Country
United States
Facility Name
St Vincent's Hospital Sydney
City
Darlinghurst
State/Province
New South Wales
ZIP/Postal Code
2010
Country
Australia
Facility Name
Calvary Mater Newcastle
City
Waratah
State/Province
New South Wales
ZIP/Postal Code
2298
Country
Australia
Facility Name
Ashford Cancer Centre Research
City
Kurralta Park
State/Province
South Australia
ZIP/Postal Code
5037
Country
Australia
Facility Name
Breast Cancer Research Centre-WA
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Linear Clinical Research
City
Nedlands
State/Province
Western Australia
ZIP/Postal Code
6009
Country
Australia
Facility Name
Institut Jules Bordet
City
Brussel - Capital
ZIP/Postal Code
1070
Country
Belgium
Facility Name
Universitair Ziekenhuis Antwerpen
City
Edegem
ZIP/Postal Code
2650
Country
Belgium
Facility Name
Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
City
Leuven
ZIP/Postal Code
3000
Country
Belgium
Facility Name
Institut Curie
City
Paris
ZIP/Postal Code
75248
Country
France
Facility Name
Institut de Cancérologie de l'Ouest Centre René Gauducheau
City
Saint Herblain Cedex
ZIP/Postal Code
44805
Country
France
Facility Name
ICANS_Institut de Cancerologie Strasbourg Europe
City
Strasbourg
ZIP/Postal Code
67033
Country
France
Facility Name
Gustave Roussy
City
Villejuif Cedex
ZIP/Postal Code
94805
Country
France
Facility Name
Hyogo Cancer Center
City
Akashi
State/Province
Hyogo
ZIP/Postal Code
673-8558
Country
Japan
Facility Name
National Cancer Center Hospital
City
Chuo-ku
State/Province
Tokyo
ZIP/Postal Code
104-0045
Country
Japan
Facility Name
Severance Hospital, Yonsei University Health System
City
Seoul
State/Province
Korea
ZIP/Postal Code
03722
Country
Korea, Republic of
Facility Name
Seoul National University Hospital
City
Seoul
State/Province
Seoul, Korea
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Asan Medical Center
City
Seoul
State/Province
Seoul-teukbyeolsi [Seoul]
ZIP/Postal Code
05505
Country
Korea, Republic of
Facility Name
Samsung Medical Center
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Hospital Universitari Vall d'Hebron
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Hospital Clinic I Provincial
City
Barcelona
ZIP/Postal Code
08036
Country
Spain
Facility Name
Hospital General Universitario Gregorio Marañon
City
Madrid
ZIP/Postal Code
28007
Country
Spain
Facility Name
Hospital Universitario Ramón y Cajal
City
Madrid
ZIP/Postal Code
28034
Country
Spain
Facility Name
Hospital Clinico San Carlos
City
Madrid
ZIP/Postal Code
28040
Country
Spain
Facility Name
Hospital Universitario 12 de Octubre
City
Madrid
ZIP/Postal Code
28041
Country
Spain
Facility Name
Fundación Jiménez Díaz-Oncology
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Hospital Madrid Norte Sanchinarro
City
Madrid
ZIP/Postal Code
28050
Country
Spain
Facility Name
Fundación Instituto Valenciano de Oncología
City
Valencia
ZIP/Postal Code
46009
Country
Spain
Facility Name
Hospital Clínico Universitario de Valencia
City
Valencia
ZIP/Postal Code
46010
Country
Spain
Facility Name
Kaohsiung Medical University Chung-Ho Memorial Hospital
City
Kaohsiung
ZIP/Postal Code
807
Country
Taiwan
Facility Name
China Medical University Hospital
City
Taichung
ZIP/Postal Code
40447
Country
Taiwan
Facility Name
National Cheng-Kung Uni. Hosp.
City
Tainan
ZIP/Postal Code
704
Country
Taiwan
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Facility Name
Mackay Memorial Hospital
City
Taipei
ZIP/Postal Code
10449
Country
Taiwan
Facility Name
Taipei Veterans General Hospital
City
Taipei
ZIP/Postal Code
11217
Country
Taiwan

12. IPD Sharing Statement

Plan to Share IPD
No
Links:
URL
https://trials.lillytrialguide.com/en-US/trial/2zSLrHO7ERDGXZvPbUVdZm
Description
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer

Learn more about this trial

A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer

We'll reach out to this number within 24 hrs